A large-scale review explains the key differences.
A scientific review funded by canola oil stakeholders reveals the potential health value of canola oil compared to oils high in saturated fats.
Canola (Brassica napus, B. rapa, and B. juncea) is a relative of rapeseed, bred for low levels of erucic acid and glucosinolates. Its oil is the third most-produced vegetable oil in the world, after palm oil and soybean oil.
Out of 270 studies found on canola, researchers deemed 40 eligible for inclusion, including studies on canola and cholesterol, heart disease, inflammation, insulin, oxidized LDL cholesterol, energy metabolism, and cancer.
Based on their findings, the researchers say considerable data supports canola oil for lowering total cholesterol, especially when canola oil is consumed in place of oils high in saturated fat or when supplementation is compared to unchanged Western diets. In 29 studies assessing circulatory cholesterol levels, a wide range of significant cholesterol reductions were observed with canola oil. It seems to have this effect on healthy subjects and those with elevated cholesterol, and reductions in LDL cholesterol are comparable.
The cholesterol benefits of canola oil can largely be attributed to the oil’s high composition of monounsaturated fats-about 61%. Odd as it may sound, this unsaturated fat profile likely has a beneficial effect on insulin, too. While research is a bit limited on canola oil consumption and glucose and insulin levels, the researchers have found that, “In general, canola oil–based diets show positive results in modulating glucose and insulin levels compared with saturated fatty acid–based diets.”
Fat profile aside, the antioxidant value in canola oil is equally provocative. Compared to oils higher in saturated fat, canola oil is high in vitamin E tocopherols, especially γ-tocopherol. Studies suggest that lower ratios of α- to γ-tocopherols are associated with lower heart disease incidence. And the presence of antioxidative vitamin E can help protect canola’s unsaturated faty acids from oxidation.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.